BACKGROUND: Despite recommendations that patients rating their own health using utility and preference measures such as the feeling thermometer (FT) and standard gamble (SG) should also rate hypothetical marker states, little evidence supports marker state use. We evaluated whether the administration of marker states improves measurement properties of the FT and SG. METHODS: We randomized 217 patients with gastroesophageal reflux disease to complete the FT (self-administered) and SG with marker states (FT+ / SG+, n = 112) or without marker states (FT- / SG-, n = 105) before and after 4 weeks of treatment with a proton pump inhibitor, esomeprazole. Patients also completed other health-related quality of life instruments. RESULTS: The use of marker states did not influence baseline utility scores (FT+ 0.66, FT- 0.68; SG+ 0.77, SG- 0.78, on a scale from 0 [dead] to 1.0 [full health]). Improvement after therapy was 0.21 in FT+ and 0.15 in FT- (both P < 0.001; difference between FT+ and FT- = 0.06, P = 0.02). Improvement in SG+ was 0.07 (P < 0.001) and 0.06 in SG- (P = 0.003) (difference between SG+ and SG- = 0.01, P = 0.63). Correlations with other health-related quality of life scores were generally stronger, with some statistically significant differences in correlations, for FT+ compared with FT-, but tended to be weaker for SG+ compared with SG-. CONCLUSION: The administration of marker states improved the responsiveness and validity of the FT but not of the SG. Decisions about administering marker states should depend on whether the FT and SG is of primary interest and the importance of optimal validity and responsiveness relative to competing objectives such as efficiency.
RCT Entities:
BACKGROUND: Despite recommendations that patients rating their own health using utility and preference measures such as the feeling thermometer (FT) and standard gamble (SG) should also rate hypothetical marker states, little evidence supports marker state use. We evaluated whether the administration of marker states improves measurement properties of the FT and SG. METHODS: We randomized 217 patients with gastroesophageal reflux disease to complete the FT (self-administered) and SG with marker states (FT+ / SG+, n = 112) or without marker states (FT- / SG-, n = 105) before and after 4 weeks of treatment with a proton pump inhibitor, esomeprazole. Patients also completed other health-related quality of life instruments. RESULTS: The use of marker states did not influence baseline utility scores (FT+ 0.66, FT- 0.68; SG+ 0.77, SG- 0.78, on a scale from 0 [dead] to 1.0 [full health]). Improvement after therapy was 0.21 in FT+ and 0.15 in FT- (both P < 0.001; difference between FT+ and FT- = 0.06, P = 0.02). Improvement in SG+ was 0.07 (P < 0.001) and 0.06 in SG- (P = 0.003) (difference between SG+ and SG- = 0.01, P = 0.63). Correlations with other health-related quality of life scores were generally stronger, with some statistically significant differences in correlations, for FT+ compared with FT-, but tended to be weaker for SG+ compared with SG-. CONCLUSION: The administration of marker states improved the responsiveness and validity of the FT but not of the SG. Decisions about administering marker states should depend on whether the FT and SG is of primary interest and the importance of optimal validity and responsiveness relative to competing objectives such as efficiency.
Authors: Holger J Schünemann; Roger Goldstein; M Jeffery Mador; Douglas McKim; Elisabeth Stahl; Lauren E Griffith; Ahmed M Bayoumi; Peggy Austin; Gordon H Guyatt Journal: Qual Life Res Date: 2006-02 Impact factor: 4.147
Authors: Wojtek Wiercioch; Robby Nieuwlaat; Elie A Akl; Robert Kunkle; Kendall E Alexander; Adam Cuker; Anita Rajasekhar; Pablo Alonso-Coello; David R Anderson; Shannon M Bates; Mary Cushman; Philipp Dahm; Gordon Guyatt; Alfonso Iorio; Wendy Lim; Gary H Lyman; Saskia Middeldorp; Paul Monagle; Reem A Mustafa; Ignacio Neumann; Thomas L Ortel; Bram Rochwerg; Nancy Santesso; Sara K Vesely; Daniel M Witt; Holger J Schünemann Journal: Blood Adv Date: 2020-05-26
Authors: Zoran Kvrgic; Gladys B Asiedu; Cynthia S Crowson; Jennifer L Ridgeway; John M Davis Journal: Arthritis Care Res (Hoboken) Date: 2018-09-04 Impact factor: 4.794
Authors: Peter Wahlqvist; Gordon H Guyatt; David Armstrong; Alessio Degl'innocenti; Diane Heels-Ansdell; Samer El-Dika; Ingela Wiklund; Carlo A Fallone; Lisa Tanser; Sander Veldhuyzen van Zanten; Peggy Austin; Alan N Barkun; Naoki Chiba; Holger J Schünemann Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981
Authors: Pablo Alonso-Coello; Shanil Ebrahim; Gordon H Guyatt; Kari A O Tikkinen; Mark H Eckman; Ignacio Neumann; Sarah D McDonald; Elie A Akl; Shannon M Bates Journal: BMC Pregnancy Childbirth Date: 2012-05-30 Impact factor: 3.007
Authors: Dennis W Raisch; Patricia Feeney; David C Goff; K M Venkat Narayan; Patrick J O'Connor; Ping Zhang; Don G Hire; Mark D Sullivan Journal: Cardiovasc Diabetol Date: 2012-07-11 Impact factor: 9.951
Authors: Samer El-Dika; Gordon H Guyatt; David Armstrong; Alessio Degl'innocenti; Ingela Wiklund; Carlo A Fallone; Lisa Tanser; Sander Veldhuyzen van Zanten; Diane Heels-Ansdell; Peter Wahlqvist; Naoki Chiba; Alan N Barkun; Peggy Austin; Holger J Schünemann Journal: BMC Gastroenterol Date: 2005-07-10 Impact factor: 3.067
Authors: Pablo Alonso-Coello; Victor M Montori; Ivan Solà; Holger J Schünemann; Philipe Devereaux; Cathy Charles; Mercè Roura; M Gloria Díaz; Juan Carlos Souto; Rafael Alonso; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ana Isabel Diez; Ignasi Gich; Gordon Guyatt Journal: BMC Health Serv Res Date: 2008-10-27 Impact factor: 2.655